Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 314

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 314
---
 cooperate in good faith until the date of the SPAC Shareholders’ approval to find an alternative arrangement reasonably acceptable to all parties; provided that such arrangement would not result, following the Closing, in such option holders having any rights, whether by ownership or otherwise, to any MultiplAI Shares. As consideration for the sale of the ordinary shares of MultiplAI, the MultiplAI Shareholders at the Closing would receive: (i) Parent’s ordinary shares pro rata to the number of MultiplAI’s ordinary shares held by each MultiplAI Shareholder at Closing and calculated in accordance with the MultiplAI Share Purchase Agreement, and (ii) if applicable, additional earn -outshares of the Parent, subject to the terms and conditions of the MultiplAI Share Purchase Agreement. The closing of the MultiplAI Acquisition was conditioned on the closing of the Business Combination. In connection with the MultiplAI Contribution, the Parent and the Company would enter into an agreement in form and substance reasonably satisfactory to SPAC providing for the contribution by the Parent of MultiplAI Shares to the Company in exchange for the 4,000,000 Company Shares. Reseller License Agreement On August 11, 2024, MultiplAI, the Company, and Parent entered into a binding term sheet for the Reseller License Agreement, pursuant to which MultiplAI will grant OmnigenicsAI an exclusive license to market certain products in Latin America through December 31, 2030. Concurrently with the Restructuring, Parent has agreed to contribute to OmnigenicsAI certain receivables owed by MultiplAI to Parent pursuant to certain loan agreements. This binding term sheet was entered into in the context of negotiations relating to the termination of the MultiplAI Share Purchase Agreement. The material terms of the binding term sheet set the following terms for the Reseller License Agreement. The main terms of the Reseller License Agreement are: •Exclusivity Rights: as part of this arrangement, OmnigenicsAI will pay a reseller access fee of $155,260 in consideration for exclusivity rights over the MultiplAI Products, effective on January1, 2025; 156 •Pilot Products: the remaining balance of the loan will provide OmnigenicsAI the option to receive 200 products annually for the first three years for pilot and sales initiatives, valued at a baseline price of $400 per unit, further reducing the remaining debt of $240,000 owed to Parent; •Sales Targets and Termination: Omnigenics